Atherosclerotic Cardiovascular Disease
The Atherosclerotic Cardiovascular Disease pipeline: 116 tracked drugs, 17 approved for this indication.
17 approved / phase 441 Phase 31 Phase 2/324 Phase 24 Phase 1/219 Phase 110 preclinical / unstaged
Compare the share prices of listed companies in Atherosclerotic Cardiovascular Disease →
Total attributable cost
$69.5B
$3,494/patient
Drug spend
$22.7B
$1,139/patient
All severities (2015-2018 NHANES cycle) · US
The Atherosclerotic Cardiovascular Disease pipeline
Key trial results for every approved and late-stage drug: Atherosclerotic Cardiovascular Disease results by drug.